A5060742428- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Pancreatitis Pathology and Treatment
- Hepatitis B Virus Studies
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Liver Disease and Transplantation
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
- Drug-Induced Hepatotoxicity and Protection
- MicroRNA in disease regulation
- Hip disorders and treatments
- Orthopaedic implants and arthroplasty
- Neuroendocrine Tumor Research Advances
- Educational Technology and Assessment
- MRI in cancer diagnosis
- Angiogenesis and VEGF in Cancer
- PI3K/AKT/mTOR signaling in cancer
- SARS-CoV-2 and COVID-19 Research
- Pharmaceutical Practices and Patient Outcomes
Ospedale Castelfranco Veneto
2021-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
Istituto Oncologico Veneto
2020-2024
University of Padua
2016-2021
Azienda Ospedaliera di Padova
2017
BackgroundNeoangiogenesis plays a crucial role in the progression of hepatocellular carcinoma (HCC), and concerns have been raised about neoangiogenesis on effectiveness transarterial chemoembolization (TACE).AimIn this study, we aimed to evaluate Vascular Endothelial Growth Factor (VEGF) Hypoxia-Inducible Factor-1α (HIF-1α) as circulating prognostic biomarkers HCC patients treated with TACE.MethodsBlood samples were collected from 163 before (t0) four weeks after TACE (t1).ResultsHigher...
Abstract Background & Aims According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding and treatment large tumours. We aimed at evaluating appropriate for (>5 cm) (HCC). Methods From Italian database, we selected 924 patients with small HCC (2‐5 cm; SEM‐HCC), 163 larger tumours LEM‐HCC) 1048 intermediate stage B). Results LEM‐HCC...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited survival. Curative opportunities are only available for patients resectable cancer. Palliative chemotherapy the current standard of care unresectable tumors. Numerous efforts have been made to investigate new therapeutic strategies PDAC. Immunotherapy has found be effective in treating tumors high microsatellite instability (MSI-H), including The ability Endoscopic Ultrasound Fine Needle Biopsy (EUS-FNB)...
Appears in: ICERI2023 Proceedings Publication year: 2023Pages: 7278-7282ISBN: 978-84-09-55942-8ISSN: 2340-1095doi: 10.21125/iceri.2023.1810Conference name: 16th annual International Conference of Education, Research and InnovationDates: 13-15 November, 2023Location: Seville, Spain
Background: Only 0.1-2% of acute pancreatitis seems to be drug-induced, being this etiology probably underestimated and often classified as idiopathic. Loperamide is an opiate with peripheral action, used in the treatment diarrhea. Since 2012 it belongs FDA list drugs potentially able cause pancreatitis, because its capacity modulating secretion from exocrine pancreas causing sphincter Oddi dysfunction.Case presentation: We report cases three women, admitted our hospital for pancreatitis. In...